The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4
- Author:
Kyung Hee HAN
1
;
Noh Hyun PARK
;
Jin Ju KIM
;
Sunmie KIM
;
Hee Seung KIM
;
Maria LEE
;
Yong Sang SONG
Author Information
- Publication Type:Original Article
- Keywords: Tumor Markers; CA 125 Antigen; HE4 Protein, Human; Ovarian Epithelial Cancer; Menopause
- MeSH: Biomarkers, Tumor; CA-125 Antigen; Discrimination (Psychology); Epididymis; Female; Humans; Male; Medical Records; Menopause; Ovarian Cysts; Ovarian Neoplasms; Postmenopause; Premenopause; Retrospective Studies; ROC Curve; Roma; Sensitivity and Specificity
- From:Journal of Gynecologic Oncology 2019;30(6):e83-
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: To identify the power of tumor markers for predicting ovarian cancer according to menopausal status. METHODS: The medical records of 876 women with ovarian cysts were retrospectively reviewed. Cancer antigen 125 (CA 125), human epididymis protein 4 (HE4), and Risk of Ovarian Malignancy Algorithm (ROMA) were analyzed. Sensitivity, specificity, and the receiver operating characteristic (ROC) curve analyses of these tumor markers were evaluated. RESULTS: The sensitivity of ROMA was 66.7% and the specificity was 86.8% to detect ovarian malignancy. The patients were divided into 2 groups according to menopausal status: premenopause (n=532, 60.7%) and postmenopause (n=344, 39.3%). For diagnostic accuracy, ROMA was lower than HE4 in premenopausal women (82.7% vs. 91.4%) and lower than CA 125 in postmenopausal women (86.9% vs. 88.7%). The ROC curve analysis revealed that the power of ROMA was not significantly better than that of HE4 in premenopausal women (area under the curve [AUC], 0.731 vs. 0.732, p=0.832), and it was also not significantly better than that of CA 125 in postmenopausal women (AUC, 0.871 vs. 0.888, p=0.440). CONCLUSION: The discrimination power of tumor markers for ovarian cancer was different according to menopausal status. In predicting ovarian malignancy, ROMA was neither superior to HE4 in premenopausal women nor superior to CA 125 in postmenopausal women.
